The activity of pathway-selective estrogen receptor ligands in experimental septic shock

Shock

Volumn 24, Issue 6, 2006, Pages 535-540

  Opal, Steven M ^a   Palardy, John E ^a   Cristofaro, Patricia ^a   Parejo, Nicolas ^a   Jhung, Jhung W ^a   Keith Jr , James C ^b   Chippari, Sue ^c   Caggiano, Thomas J ^c   Steffan, Robert J ^c   Chadwick, Christopher C ^c   Harnish, Douglas C ^c  

^a MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

^b PFIZER INC   (United States)

^c Memorial Hospital of Rhode Island ^*

Author keywords

Estrogen receptor agonists; Estrogens; Sepsis; Septic shock; Severe sepsis

Indexed keywords

CYCLOPHOSPHAMIDE; ESTROGEN; ESTROGEN RECEPTOR; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIGAND; LUCIFERASE; MONOCYTE CHEMOTACTIC PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; WAY 169916; WAY 204688;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ELECTRON MICROSCOPY; INFLAMMATION; MOUSE; NEUTROPENIA; NONHUMAN; PSEUDOMONAS AERUGINOSA; SEPTIC SHOCK; SMALL INTESTINE MUCOSA;

EID: 33646774355     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.shk.0000183388.90895.cb     Document Type: Article

References (30)

1. Martin GS, Mannino DM, Eaton S, Moss M: Epidemiology of sepsis in the United States from 1979-2000. N Engl J Med 348:1546-1557, 2003.
2. Wichman MW, Inthorn D, Andress JH, Schildberg FW: Incidence and mortality of severe sepsis in surgical intensive care patients: the influence of patient gender on disease process and outcome. Intensive Care Med 26:167-172, 2000.
3. Schroder J, Kahlke V, Staubach KH, Zabel P, Stuber F: Gender differences in human sepsis. Arch Surg 133:1200-1205, 1998.
4. Hubacek JA, Stuber F, Frohlich D, Book M, Wetegrove S, Ritter M, Rothe G, Schmitz G: Gene variants of the bactericidal/permeability increasing protein and lipopolysaccharide binding protein in sepsis patients: gender-specific predisposition to sepsis. Crit Care Med 29:557-561, 2001.
5. Zellweger R, Wichmann MW, Ayala A, Stein S, DeMaso CM, Chaudry IH: Females in proestrus state maintain splenic immune functions and tolerate sepsis better than males. Crit Care Med 25:106-110, 1997.
6. Diodato MD, Knoferl MW, Schwacha MG, Bland KI, Chaudry IH: Gender differences in the inflammatory response and survival following haemorrhage and subsequent sepsis. Cytokine 14:162-169, 2001.
7. Pung OJ, Luster MI: Toxoplasma gondii: decreased resistance to infection in mice due to estrogen. Exp Parasitol 61:48-56, 1986.
8. Pung OJ, Tucker AN, Vore SJ, Luster MI: Influence of estrogen on host resistance: increased susceptibility of mice to Listeria monocytogenes correlates with depressed production of interleukin-2. Infect Immun 50:91-96, 1985.
9. Pung OJ, Luster MI, Hayes HT, Rader J: Influence of steroidal and nonsteroidal sex hormones on host resistance in mice: increased susceptibility to Listeria monocytogenes after exposure to estrogenic hormones. Infect Immun 46:301-307, 1984.
10. O'Keefe GE, Hunt JL, Purdue GF: An evaluation of risk factors for mortality after burn trauma and the identification of gender-dependent differences in outcomes. J Am Coll Surg 192:153-160, 2001.
11. Kuiper GGJM, Carlsson B, Grandian K, Enmark E, Haggblad J, Nilsson S, Gustafsson JA: Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptor α and β. Endocrinology 138:863-870, 1997.
12. Couse JF, Lindzey J, Grandien K, Gustafsson JA, Korach TS: Tissue distribution and quantitative analysis of estrogen receptor-α (ER α) messenger ribonucleic acid in the wild-type and ER α-knockout mouse. Endocrinology 138:4613-4621, 1997.
13. Harris HA, Bapat AR, Gonder DS, Frail DE: The ligand binding profiles of estrogen receptors α and β are species dependent. Steroids 67:379-384, 2002.
14. Kuiper GGJM, Enmark E, Pelto Huikko M, Nilsson G, Gustafsson JA: Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 93:5925-5930, 1996.
15. Stein B, Yang MX: Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-κB and C/EBP β. Mol Cell Biol 15:4971-4979, 1995.
16. Ray A, Prefontaine KE, Ray P: Down-modulation of interleukin-6 gene expression by 17 β-estradiol in the absence of high-affinity DNA binding by the estrogen receptor. J Biol Chem 269:12940-12946, 1994.
17. Ray P, Ghosh SK, Shang DH, Ray A: Repression of interleukin-6 gene expression by 17 β-estradiol: inhibition of the DNA-binding activity of the transcription factors NF-IL6 and NF-κB by the estrogen receptor. FEBS Lett 409:79-85, 1997.
18. Deshpande R, Khalili H, Pergolizzi RG, Michael SD, Chang MD: Estradiol down-regulates LPS-induced cytokine production and NFκB activation in murine macrophages. Am J Reprod Immunol 38:46-54, 1997.
19. Sun WH, Keller ET, Stebler BS, Ershler WB: Estrogen inhibits phorbol ester-induced IκBα transcription and protein degradation. Biochem Biophys Res Commun 244:691-695, 1998.
20. Harnish DC, Scicchitano MS, Adelman SJ, Lyttle CR, Karathanasis SK: The role of CBP in estrogen receptor cross-talk with nuclear factor-κB in HepG2 cells. Endocrinology 141:3403-3411, 2000.
21. Phal HL: Activators and target genes of Rel/NF-κB transcription factors. Oncogens 18:6853-6866, 1999.
22. Böhrer H, Qiu F, Zimmermann T, Zhang Y, Jllmer T, Männel D, Böttiger BW, Stern DM, Waldherr R, Hans-Detlev S, Ziegler R, Bierhaus A, Martin E, Nawroth P: Role of NFκB in the mortality of sepsis. J Clin Invest 100:972-985, 1997.
23. Arnalich F, Garcia-Palomero E, Lopez J, Jimenez M, Madero R, Renart J, Vazquez JJ, Montiel C: Predictive value of nuclear factor κB activity and plasma cytokine levels in patients with sepsis. Infect Immun 68:1942-1945, 2000.
24. Abraham E: Nuclear factor-κB and its role in sepsis associated organ failure. J Infect Dis 187:S364-S369, 2003.
25. Sha WC, Liou HC, Tuomanen EI, Baltimore D: Targeted disruption of the p50 subunit of NFκB leads to multifocal defects in immune responses. Cell 80:321-330, 1995.
26. Chadwick CC, Chippari S, Matelan E, Borges-Marcucci L, Eckert AM, Keith JC Jr, Albert LM, Leathurby Y, Harris HA, Bhat RA, Ashwell M, Trybulski E, Winneker RC, Adelman SJ, Steffan RJ, Harnish DC: Identification of pathway-selective estrogen receptor ligands that inhibit NF-κB transcriptional activity. Proc Natl Acad Sci USA 102:2543-2548, 2005.
27. Harris HA, Albert LM, Leathurby Y, Malamas MS, Mewshaw RE, Miller CP, Kharode YP, Marzolf J, Komm BS, Winneker RC, Frail DE, Henderson RA, Zhu Y, Keith JC Jr.: Evaluation of an estrogen receptor-β agonist in animal models of human disease. Endocrinology 144:4241-4249, 2003.
28. Keith JC Jr., Albert LM, Leathurby Y, Follettie M, Wang L, Borges-Marcucci L, Chadwick CC, Steffan RJ, Harnish DC: The utility of pathway selective estrogen receptor ligands that inhibit nuclear factor-κB transcriptional activity in models of rheumatoid arthritis. Arthritis Res Ther 7:R427-R438, 2005.
29. Opal SM, Sypek JP, Keith JC Jr., Schaub RG, Palardy JE, Parejo NA: Evaluation of the safety of recombinant P-selectin glycoprotein ligand immunoglobulin G fusion peptide in experimental models of localized and systemic infection. Shock 15:285-290, 2001.
30. Opal SM, Keith JC Jr., Jhung J, Palardy JE, Parejo N, Marchese E, Maganti V: Orally administered recombinant human interleukin-11 is protective in experimental neutropenic sepsis. J Infect Dis 187:70-76, 2003.